Pillarisetti, Kodandaram

Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma

Chari, A., Minnema, M. C., Berdeja, J. G., Oriol, A., van de Donk, N. W. C. J., Rodríguez-Otero, P., Askari, E., Mateos, M.-V., Costa, L. J., Caers, J., et al. (2022) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 744

A T-cell–redirecting bispecific G-protein–coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma

Pillarisetti, K., Edavettal, S., Mendonça, M., Li, Y., Tornetta, M., Babich, A., Majewski, N., Husovsky, M., Reeves, D., Walsh, E., et al. (2020) · Blood

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 174

Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma

Pillarisetti, K., Powers, G., Luistro, L., Babich, A., Baldwin, E., Li, Y., Zhang, X., Mendonça, M., Majewski, N., Nanjunda, R., et al. (2020) · Blood Advances

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 144

GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review

Rodriguez-Otero, P., van de Donk, N. W. C. J., Pillarisetti, K., Cornax, I., Vishwamitra, D., Gray, K., Hilder, B., Tolbert, J., Renaud, T., Masterson, T., et al. (2024) · Blood Cancer Journal

Multiple Myeloma Research and TreatmentsCAR-T cell therapy research

Cited by 113

Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab

Frerichs, K. A., Broekmans, M. E. C., Marin Soto, J. A., van Kessel, B., Heymans, M. W., Holthof, L. C., Verkleij, C. P. M., Boominathan, R., Vaidya, B., Sendecki, J., et al. (2020) · Clinical Cancer Research

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 94